Overview
Drug discovery and development is a complex and tedious process that requires a significant amount of resources and capital investment (~USD 2.6 billion). In fact, on an average, the journey from the establishment of initial proof-of-concept to commercial launch, is estimated to take around 10-12 years. However, only a small fraction of early stage therapeutic candidates are able to make it past preclinical testing, into clinical evaluation. Further, even fewer clinical stage candidates are eventually approved for commercialization. Given the growing complexity in drug discovery research, the overall expenditure on pharmaceutical / biotechnology R&D has steadily increased over time. Specifically, in 2019, R&D spending was estimated to be around USD 182 billion, with more than 16,000 drug molecules evaluated during the course of the whole year. The industry is presently under tremendous pressure to not only identify ways to mitigate the risks of failure of drug discovery programs, but also to meet the expectations / medical needs of a growing patient population.
Despite its many advantages, high-throughput screening (HTS) is an expensive process and pharmacological leads generated via this process have been associated with high attrition rates during preclinical development. In addition, this approach is also limited in terms of the number of compounds that can be developed and stored in compound libraries. Fragment-based drug discovery (FBDD), is a relatively new hit screening approach. which has been shown to offer a number of benefits, including a cost advantage and the potential to enable the generation of hits with improved physiochemical properties, over HTS. In this context, it is worth highlighting that three marketed drugs, namely Vemurafenib (ZELBORAF®), Venetoclax (VENCLEXTA®), and Erdafitinib (BALVERSA™), originated from fragment-based library screens. Nearly 40 candidates discovered via the FBDD approach are in clinical trials. In fact, currently, over 50% of discovery projects are estimated to be using the FBDD approach, which uses biophysical techniques such as X ray crystallography and nuclear magnetic resonance. Further, the availability of bespoke fragment collections designed against individual biological targets / target families is expected to facilitate the discovery of potent pharmaceutical leads against more challenging targets, such as protein-protein interactions and allosteric sites on enzymes.
Scope of the Report
The “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
In addition to other elements, the study includes:
- A detailed review of the overall landscape of fragment-based drug discovery library and service providers along with the information on type of product (library and technology), type of service offered (fragment screening and fragment optimization), type of technique used (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance, and other screening techniques), other services offered (target identification / validation, hit identification, hit-to-lead / lead generation, lead optimization), and end user (industry, academia, and contract research organizations).
- Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered). Each profile features a brief overview of the company, its financial information (if available), fragment-based library and service portfolio, information on other drug discovery services, recent developments and an informed future outlook.
- An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, mergers and acquisitions, product development and commercialization agreements, commercialization agreements, distribution and supply agreements, product integration agreements, service agreements, and other relevant types of deals.
- A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
- An insightful competitiveness analysis of fragment-based drug discovery library and service providers, based on supplier power (based on the years of experience of service provider) and key specifications, such as type of product, number of screening techniques, and the number of deals signed between 2015-2020.
- An analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.
One of the key objectives of the report was to estimate the existing market size and the future opportunity for fragment-based drug discovery library and services, over the next decade. Based on multiple parameters, such as annual number of drug discovery projects, outsourcing profile, and adoption of fragment-based drug discovery approach, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of technique (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance and other screening techniques), [B] type of service (library screening, fragment screening and fragment optimization), [C] end user (industry, academia and contract research organizations), and [D] key geographical regions (US, Canada, Germany, France, Italy, Spain, rest of Europe, Japan, China, and India). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:
- Jean-Yves Ortholand, Co-founder & Chief Executive Officer, Edelris
- Björn Walse, Chief Executive Officer, SARomics Biostructures
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Table of Contents
Companies Mentioned
- 2bind
- Accelero Biostructures
- Advanced Chemistry Development (ACD / Labs)
- Agilent Technologies
- Allesh Biosciences Labs
- Altaris Capital Partners
- Astex Pharmaceuticals
- AstraZeneca
- Aunova Medchem
- Aurora Fine Chemicals
- Axxam
- Basilea Pharmaceutica
- Beactica
- Bellvitge Biomedical Research Institute (IDIBELL)
- BioAscent
- BioBlocks
- BioPredict
- BioSolveIT
- BOC Sciences
- Boehringer Ingelheim
- Bruker
- C4X Discovery
- Cambridge Crystallographic Data Centre
- Cambridge MedChem Consulting
- Carna Biosciences
- Center for Drug Design and Discovery
- Centre for Chemical Biology and Therapeutics
- Charles River Laboratories
- CHDI Foundation
- ChemAxon
- ChemBridge
- ChemDiv
- Chemical Computing Group
- Collaborative Drug Discovery
- Collidion
- Columbia University
- ComInnex
- Conifer Point
- CreaGen
- Creative Biolabs
- Creative Biostructure
- CRELUX
- Creoptix
- Cresset
- CrystalsFirst
- Daiichi Sankyo
- Danaher
- Diamond Light Source
- Discover Drugs
- Domainex
- Dong-A ST
- DyNAbind
- Edelris
- Enamine
- Evotec
- Exscientia
- Fidelta
- Forge Therapeutics
- ForteBio
- GE Healthcare Life Sciences
- Gotham Therapeutics
- Helmholtz-Zentrum Berlin
- Heptares Therapeutics
- Heriot-Watt University
- Inte:Ligand
- IOTA Pharmaceuticals
- Jena Bioscience
- Jubilant Biosys
- Key Organics
- Keymodule
- Kinetic Discovery
- Kymab
- LeadInvent Technologies
- leadXpro
- LEO Pharma
- LG Chem
- Life Chemicals
- Ligand Pharmaceuticals
- Liverpool ChiroChem
- MAX IV Laboratory
- Max Planck Institute
- Maybridge
- Medicilon
- Medicines Discovery Catapult
- Merck
- Mestrelab Research
- MilliporeSigma
- Molecular Cornerstones
- Molecular Devices
- NMX Research and Solutions
- Northwestern University
- NovaData Solutions
- NovAliX
- o2h discovery
- OMass Therapeutics
- omicX
- OpenEye Scientific Software
- Optibrium
- Organochem
- Origenis
- OTAVAchemicals
- Otsuka Pharmaceutical
- PeptiDream
- Pfizer
- Pharmacelera
- Pharmaron
- PhoreMost
- Pierre Fabre
- Plex Pharmaceuticals
- Plexxikon
- PMI BioPharma Solutions
- Prestwick Chemical
- Profacgen
- Prosarix
- Proteros Biostructures
- Pyxis Discovery
- QuantumBio
- Reaction Biology
- Reaxense
- Red Glead Discovery
- RxCelerate
- SARomics Biostructures
- Selcia
- Selvita
- SensiQ
- Servier
- Shamrock Structures
- Shanghai ChemPartner
- Sharp Edge Labs
- Sierra Sensors
- SilcsBio
- Silicon Kinetics
- Sosei Heptares
- Spanish National Cancer Research Centre (CNIO)
- SpectralWorks
- SpiroChem
- Sprint Bioscience
- Structure based Design
- Sygnature Discovery
- SynphaTec Japon
- Taisho Pharmaceutical
- Takeda Pharmaceutical
- The Wistar Institute
- TimTec
- Universitat Autònoma de Barcelona
- University of Cambridge
- University of Nottingham
- Vernalis Research
- Viva Biotech
- Vlaams Instituut voor Biotechnologie
- WuXi AppTec
- Xtal BioStructures
- Zastra Innovations
- Zenobia Fragments
- ZoBio
Methodology
LOADING...